Cancer diagnostics company Biomoda, Inc. received Notice of Allowance for a U.S. Patent application on a quantitative method for scoring cells labeled with the CyPath® assay to determine whether cells are dysplastic or carcinomic by measuring the photon emission rate.
"This invention is an important weapon in our arsenal of cancer diagnostic tools because it provides the objective methodology for reading samples labeled with the CyPath® reagent," said Biomoda President John Cousins. "Lab technicians anywhere in the world will have a measurable, quantitative system to accurately and inexpensively read body fluid and tissue samples for cancer cells."
Biomoda's CyPath® reagent for the early detection of cancers is based on meso-tetra (4 carboxyphenyl) porphine or TCPP, a porphyrin compound that binds to cancer cells and fluoresces under specific frequencies of light. The allowed claims protect a system for verifying the spectral signature of TCPP optically and measuring the photon emission rate of TCPP-stained cancerous and precancerous cells.
The new invention titled "Method for Detecting and Prognosing Pre-Cancerous Cells Using 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine," will be Biomoda's fourth U.S. patent. Biomoda also has patents issued in Japan, Mexico, and Australia and patents pending in Europe and Canada.
Study shows AI can predict prognosis in triple-negative breast cancer